CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 101 enrolled
Drug / intervention
Golimumabbiological
Likely dose
Golimumab 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01668004
NCT01668004Phase 4Completed
CompareCT.gov

Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012

Merck Sharp & Dohme LLC·interventional·Posted Aug 17, 2012·Updated Feb 4, 2019

In Brief

A Phase 4 clinical trial evaluating Golimumab for Ankylosing Spondylitis. Completed, enrolled 101 participants.

Detailed Summary

The objective of this study is to determine the difference in the annual incidence rate of uveitis attacks in participants with ankylosing spondylitis (AS) before start initial anti-TNF therapy and after treatment with golimumab (GLM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2012
Enrollment StartSep 3, 2012
Primary CompletionApr 30, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.9 years ago

Interventions

Golimumabbiological

GLM 50 mg subcutaneously once monthly.